Immunotherapy and Liver Transplantation: The Future or the Failure?
Hepatocellular carcinoma
Immunotherapy
Liver transplantation
Outcomes
Rejection
Journal
The Surgical clinics of North America
ISSN: 1558-3171
Titre abrégé: Surg Clin North Am
Pays: United States
ID NLM: 0074243
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
medline:
14
11
2023
pubmed:
13
11
2023
entrez:
12
11
2023
Statut:
ppublish
Résumé
A quarter century has passed since the milestone study by Mazzaferro and colleagues on liver transplantation (LT) for hepatocellular carcinoma (HCC). The increasing demand for LT for HCC has led to the continued efforts to expand LT indications. Downstaging to within Milan criteria has been incorporated into the organ allocation policy for HCC in the United States in 2017 and provides acceptable long-term survival. The present review focuses on the rationale of neoadjuvant immune checkpoint inhibitor (ICI) in HCC, the experience of ICI in the pre- and posttransplant setting.
Identifiants
pubmed: 37953034
pii: S0039-6109(23)00121-4
doi: 10.1016/j.suc.2023.07.009
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
163-182Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.